1. Japan Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
FUJIFILM Holdings Corporation

FUJIFILM Holdings Corporation

FJI.F
FUJIFILM Holdings Corporationundefined flagFrankfurt Stock Exchange
19.36
EUR
-0.18
- -
23.14BMarket Cap
FUJIFILM Holdings Corporation
FJI.F
(Frankfurt Stock Exchange)

Recent

price

19.36

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
1,519.62
1,519.12
1,532.49
1,687.68
1,723.65
1,761.61
1,743.86
1,859.95
1,917.92
1,890.46
1,828.18
2,102.78
792.65
2,459.09
2,655.87
2,789
- -
Revenue per Share
43.77
30.28
37.55
56.02
81.98
83.34
98.76
107.54
108.94
102.06
151.09
175.81
60.83
202.24
216.86
229.91
- -
Basic EPS, GAAP
58.36
9.25
61.88
136.72
124.63
98.37
143.93
137.25
126.46
119.17
246.19
131.56
-31.33
-47.15
-47.18
-132.94
- -
Free Cash Flow per Basic Share
9.21
10.83
12.5
13.33
18.33
22.89
22.65
24.24
26.16
29.25
31.66
35.83
12.78
46.65
46.68
70.08
- -
Dividend per Share
1,314.39
1,373.54
1,397.7
1,436.5
1,498.1
1,586.15
1,739.23
1,852.91
2,009.89
2,125.88
2,287.29
2,421.17
736.51
2,310.32
2,468.63
2,623.5
2,620.34
Book Value per Share
1,002.22
981.96
1,053.37
1,170.84
1,301.54
1,173.42
1,270.46
1,207.68
1,139.26
950.91
1,075.19
1,288.96
494.96
1,695.21
1,867.53
2,239.98
2,237.27
Tangible Book Value per Share
1,459
1,445
1,445
1,446
1,446
1,397
1,332
1,308
1,268
1,225
1,199
1,201
3,607
1,204
1,203
1,204
1,205
Basic Weighted Avg Shares
2,217,084
2,195,293
2,214,696
2,439,953
2,492,605
2,460,383
2,322,163
2,433,365
2,431,489
2,315,141
2,192,519
2,525,773
2,859,041
2,960,916
3,195,828
3,356,969
- -
Sales/Revenue/Turnover
7.58
5.15
5.15
5.77
6.92
7.34
7.42
5.07
8.63
8.06
7.55
9.09
9.55
9.35
10.33
10.43
- -
Operating Margin (%)
157,094
147,775
141,548
141,440
122,909
124,960
117,635
127,642
129,932
122,653
123,423
132,999
142,215
150,014
150,014
172,371
- -
Depreciation Expense
63,852
43,758
54,266
80,996
118,553
116,402
131,506
140,694
138,106
124,987
181,205
211,180
219,422
243,509
260,951
276,735
- -
Net Income, GAAP
41.01
33.67
37.53
34.8
29.67
26.58
22.65
27.52
26.35
20.87
23.58
21.94
23.1
24.62
22.78
24.89
- -
Effective Tax Rate (%)
2.88
1.99
2.45
3.32
4.76
4.73
5.66
5.78
5.68
5.4
8.26
8.36
7.67
8.22
8.17
8.24
- -
Profit Margin (%)
724,385
629,624
1,014,923
1,165,275
1,320,930
1,159,440
1,354,622
1,196,585
1,028,621
829,196
791,092
745,154
740,785
408,787
455,741
460,761
460,761
Working Capital
119,314
20,334
317,592
314,968
313,045
310,388
434,843
412,502
353,533
555,823
494,297
303,967
325,460
257,939
555,600
702,551
702,551
LT Debt
1,850,871
1,856,484
2,024,786
2,198,223
2,467,416
2,231,997
2,268,058
2,298,706
2,244,841
1,993,757
2,222,157
2,524,940
2,787,860
3,173,315
3,352,682
3,844,385
3,844,385
Total Equity
4.72
3.67
3.21
3.69
4.46
4.85
4.87
3.17
5.55
5.33
4.53
6.06
6.59
5.86
6.36
5.77
- -
Return on Invested Capital (%)
2.51
1.44
1.65
2.43
3.83
3.68
4.05
4.53
3.81
3.41
5.38
6.1
6.69
7.65
7.45
7.03
- -
Return on Capital (%)
3.34
2.24
2.71
3.95
5.59
5.31
5.8
5.94
5.56
4.85
6.78
7.47
7.89
8.96
9.07
9.03
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
254,768
- -
324,462
LT Borrowings
571,872
- -
607,034
LT Finance Leases
96,176
- -
95,517
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,205
- -
1,205
Market Capitalization
4,410,884
4,005,760
3,621,070

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
1,600,471
- -
1,719,033
Cash, Cash Equivalents & STI
160,878
- -
170,553
Accounts Receivable, Net
643,838
- -
742,721
Inventories
600,118
- -
600,796
Total Current Liabilities
1,156,321
- -
1,258,272
Payables & Accruals
- -
- -
- -
ST Debt
254,768
- -
324,462
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.91%
11.64%
14.67%
Free Cash Flow
- -
- -
181.85%
Net Income, GAAP
9.82%
8.93%
6.05%
Sales/Revenue/Turnover
3.39%
8.98%
5.04%
Total Cash Common Dividend
- -
- -
50.18%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
660,759
727,711
766,941
805,505
2,960,916
2025
- -
- -
- -
- -
3,195,828
2026
- -
- -
- -
- -
3,356,969

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
45.25
49.17
50
- -
202.24
2025
- -
- -
- -
- -
216.86
2026
- -
- -
- -
- -
229.91

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
23.35
- -
23.33
- -
46.65
2025
- -
- -
- -
- -
46.68
2026
- -
- -
- -
- -
70.08
Similar Companies
Acarix AB (publ) (ACIXF)
Episurf Medical AB (EPIS-B.ST)
Sino Medical Sciences Technology Inc. (688108.SS)
Quanterix Corporation (QTRX)
Modular Medical, Inc. (MODD)
Catheter Precision, Inc. (VTAK)
Business
FUJIFILM Holdings Corporation, a Tokyo-based holding company founded in 1934 and headquartered at 7-3 Akasaka 9-chome, Minato-ku, Tokyo, oversees a multinational conglomerate focused on healthcare, electronics, business innovation, and imaging solutions; it operates worldwide across Japan, the Americas, Europe, Asia, and other regions through 270 consolidated subsidiaries and approximately 72,593 employees. The company provides products and services in healthcare, including medical imaging systems, bio-CDMO for biologics and vaccines manufacturing, life science solutions such as cell culture media and regenerative medicine; electronics, encompassing semiconductor materials, display materials like optical films for flat-panel displays, and other electronic materials including high-purity chemicals and recording media; business innovation, featuring business solutions, office equipment such as multifunction devices and printers, and graphic communications like inkjet digital presses, CTP plates, and industrial inkjet printheads; and imaging, covering consumer products including Instax instant cameras, digital cameras, color films, and photofinishing equipment as well as professional imaging tools like lenses, binoculars, and medium format cameras. Recent developments include the November 2025 completion of a new building for advanced semiconductor materials production in Shizuoka by Fujifilm; a joint research initiative launched in November 2025 with Japan's National Cancer Center to develop innovative cancer treatment technologies; the expansion in September 2025 of its strategic partnership with argenx SE to manufacture efgartigimod drug substance at the Holly Springs, North Carolina facility starting in 2028 as part of the global kojoX network; the divestiture in September 2025 of its Irvine Scientific medical media business in assisted reproductive technology to Astorg, enabling focus on core life sciences operations; the opening of new NURA health screening centers in October 2025 across Vietnam, Thailand, the Philippines, and Malaysia; and earlier acquisitions such as the 2023 purchase of Entegris' semiconductor high-purity process chemicals business for $700 million.